HCP
SUPN icon

Hexagon Capital Partners’s Supernus Pharmaceuticals SUPN Stock Holding History

Hexagon Capital Partners’s Portfolio SUPN Stock Details SUPN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-10
Closed -$328 – 1516
2025
Q1 		$328 Hold
10
– – ﹤0.01% 1711
2024
Q4 		$362 Buy
+10
New +$352 ﹤0.01% 1722

Other funds holding SUPN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
SIMG
Stephens Investment Management Group Houston, Texas $7.3B AUM 41.96% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

Hexagon Capital Partners's SUPN Position: Q2 2025 in Review

Hexagon Capital Partners sold out of Supernus Pharmaceuticals (SUPN) in Q2 2025, closing a stake of 10 shares — an estimated $328 sold.

Hexagon Capital Partners first reported a position in SUPN in Q4 2024 and held it in 2 quarters. The position peaked at $362 in Q4 2024. 295 funds tracked by Wall St. Rank hold SUPN as of Q2 2025.

  • Hexagon Capital Partners reported no remaining Supernus Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
  • Hexagon Capital Partners sold 10 Supernus Pharmaceuticals shares in Q2 2025, an estimated $328.
  • Hexagon Capital Partners first reported a position in Supernus Pharmaceuticals in Q4 2024 and held it in 2 quarters.
  • Hexagon Capital Partners's Supernus Pharmaceuticals position peaked at $362 in Q4 2024.
  • 295 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q2 2025.

Based on Hexagon Capital Partners's 13F filing for Q2 2025, filed 11 Aug 2025.